Discover how CRISPR–Cas9 is evolving from a genome-editing lab tool into a programmable protein drug. Explore viral vectors, lipid nanoparticles, and peptide-based delivery strategies that enable safe, one‑time gene editing therapies for diseases like sickle cell and inherited retinal disorders.
Learn how CRISPR-based gene editing therapy works, from Cas enzymes and guide RNA to advanced base and prime editors. Discover how these precision medicines differ from traditional drugs by targeting the genetic root cause of disease.